- Home
- SKE vs EWTX Comparison
SKE vs EWTX Comparison
Compare SKE & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKE | EWTX |
|---|---|---|
| Founded | 1979 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.3B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SKE | EWTX |
|---|---|---|
| Price | $32.87 | $30.29 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $34.71 |
| AVG Volume (30 Days) | ★ 1.3M | 1.0M |
| Earning Date | 03-30-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.53 | $10.60 |
| 52 Week High | $35.69 | $31.29 |
Technical Indicators
Market Signals| Indicator | SKE | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 58.42 | 57.79 |
| Support Level | $30.69 | $29.30 |
| Resistance Level | $34.49 | $31.26 |
| Average True Range (ATR) | 2.08 | 1.64 |
| MACD | -0.11 | -0.01 |
| Stochastic Oscillator | 67.89 | 70.16 |
Price Performance
Historical ComparisonAbout SKE Skeena Resources Limited
Skeena Resources Ltd is a mining company in development stage focusing on the construction and development of the Eskay Creek project in British Columbia. Eskay Creek is the next global gold development project and represents one of the highest-grade and lowest-cost open-pit precious metals mines, with substantial silver by-product production.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.